PMID- 34797505 OWN - NLM STAT- MEDLINE DCOM- 20220308 LR - 20220531 IS - 1865-8652 (Electronic) IS - 0741-238X (Print) IS - 0741-238X (Linking) VI - 39 IP - 1 DP - 2022 Jan TI - The Short-Term Efficacy and Safety of Brentuximab Vedotin Plus Cyclophosphamide, Epirubicin and Prednisone in Untreated PTCL: A Real-World, Retrospective Study. PG - 532-543 LID - 10.1007/s12325-021-01943-z [doi] AB - INTRODUCTION: Brentuximab vedotin (BV) showed high overall remission rates in refractory/relapsed classical Hodgkin's lymphoma (HL) and systemic anaplastic large cell lymphoma (sALCL). Although the efficacy of BV has been reported in clinical trials, its efficacy as a frontline therapy in real world for patients with CD30 positive subtypes of non-Hodgkin's lymphoma (NHL) such as peripheral T-cell lymphoma with T-follicular helper cell (TFH) phenotype (PTCL, TFH), anaplastic large-cell lymphoma (ALCL) and angioimmunoblastic T-cell lymphoma (AITL) in China has not been well documented. METHODS: Analysis of a real-world, observational, retrospective case series in patients suffering from AITL, sALCL and peripheral T-cell lymphoma with T-follicular helper phenotype (PTCL-TFH) and other types of PTCL treated with BV in frontline treatment was conducted. The patients were given treatment from May 2020 till June 28, 2021. All patients were pathologically diagnosed to have PTCL before treatment and expressed CD30. Patients received BV (1.8 mg/kg) combined with CEP (cyclophosphamide, epirubicin, prednisone acetate every 3 weeks). The primary endpoint was objective response rates (ORR), and secondary endpoints were duration of response and incidence of adverse events (AEs). Exploratory endpoints such as progression-free survival (PFS) are discussed even though after such a short period. RESULTS: Nineteen patients completed >/= 1 cycles of BV-CEP treatment (16 cases completed >/= 4 cycles, 3 cases only completed 1 cycle). Among them, the ORR reached 89.5% [CR 52.7%; partial response (PR) 36.8%]. In the ALCL group, CR reached 100% with the median duration of response of up to 8 months, while in the AITL group, the ORR was 75% and 2 patients had disease progression after treatment with BV + CEP. We also observed that BV-CEP may extend the PFS compared to traditional chemotherapy such as the CHOEP regimen (BV-CEP: not evaluable, CHOEP: 6.5 months), although the median follow-up was only 6.7 months. Adverse events (AEs), including incidence and severity of febrile neutropenia (26% patients in the BV-CEP group and 30% in the CHOEP group), were similar between groups. There was no incidence of AEs leading to treatment withdrawal or death under BV-CEP treatment. CONCLUSION: BV is a promising treatment in patients with ALCL, AITL and PTCL-TFH in frontline treatment settings. CI - (c) 2021. The Author(s). FAU - Feng, Xiaomeng AU - Feng X AD - Department of Hematology, The First Hospital of Jilin University, 3808 Jiefang Rd, Hongqi Street, Chaoyang District, Changchun, 130021, Jilin, China. FAU - Guo, Wei AU - Guo W AD - Department of Hematology, The First Hospital of Jilin University, 3808 Jiefang Rd, Hongqi Street, Chaoyang District, Changchun, 130021, Jilin, China. FAU - Wang, Yinping AU - Wang Y AD - Department of Hematology, The First Hospital of Jilin University, 3808 Jiefang Rd, Hongqi Street, Chaoyang District, Changchun, 130021, Jilin, China. FAU - Li, Jia AU - Li J AD - Department of Hematology, The First Hospital of Jilin University, 3808 Jiefang Rd, Hongqi Street, Chaoyang District, Changchun, 130021, Jilin, China. FAU - Zhao, Yangzhi AU - Zhao Y AD - Department of Hematology, The First Hospital of Jilin University, 3808 Jiefang Rd, Hongqi Street, Chaoyang District, Changchun, 130021, Jilin, China. FAU - Qu, Limei AU - Qu L AD - Department of Hematology, The First Hospital of Jilin University, 3808 Jiefang Rd, Hongqi Street, Chaoyang District, Changchun, 130021, Jilin, China. FAU - Yan, Xu AU - Yan X AD - Department of Hematology, The First Hospital of Jilin University, 3808 Jiefang Rd, Hongqi Street, Chaoyang District, Changchun, 130021, Jilin, China. FAU - Li, Junna AU - Li J AD - Department of Hematology, The First Hospital of Jilin University, 3808 Jiefang Rd, Hongqi Street, Chaoyang District, Changchun, 130021, Jilin, China. FAU - Guo, Qiang AU - Guo Q AD - Department of Hematology, The First Hospital of Jilin University, 3808 Jiefang Rd, Hongqi Street, Chaoyang District, Changchun, 130021, Jilin, China. FAU - Young, Ken H AU - Young KH AD - Department of Pathology, Duke University Medical Center and Cancer Institute, Durham, NC, USA. FAU - Bai, Ou AU - Bai O AUID- ORCID: 0000-0003-4066-9473 AD - Department of Hematology, The First Hospital of Jilin University, 3808 Jiefang Rd, Hongqi Street, Chaoyang District, Changchun, 130021, Jilin, China. baiou@jlu.edu.cn. LA - eng PT - Journal Article PT - Observational Study PT - Research Support, Non-U.S. Gov't DEP - 20211119 PL - United States TA - Adv Ther JT - Advances in therapy JID - 8611864 RN - 3Z8479ZZ5X (Epirubicin) RN - 7XL5ISS668 (Brentuximab Vedotin) RN - 8N3DW7272P (Cyclophosphamide) RN - VB0R961HZT (Prednisone) MH - *Antineoplastic Combined Chemotherapy Protocols/adverse effects MH - Brentuximab Vedotin/adverse effects MH - Cyclophosphamide/adverse effects MH - Epirubicin/adverse effects MH - Humans MH - *Lymphoma, T-Cell, Peripheral/drug therapy MH - Prednisone/adverse effects MH - Retrospective Studies PMC - PMC8799538 OTO - NOTNLM OT - Brentuximab vedotin (BV) OT - Cyclophosphamide OT - Epirubicin OT - Peripheral T cell lymphoma OT - Prednisone acetate (CEP) EDAT- 2021/11/20 06:00 MHDA- 2022/03/09 06:00 PMCR- 2021/11/19 CRDT- 2021/11/19 12:20 PHST- 2021/07/30 00:00 [received] PHST- 2021/10/01 00:00 [accepted] PHST- 2021/11/20 06:00 [pubmed] PHST- 2022/03/09 06:00 [medline] PHST- 2021/11/19 12:20 [entrez] PHST- 2021/11/19 00:00 [pmc-release] AID - 10.1007/s12325-021-01943-z [pii] AID - 1943 [pii] AID - 10.1007/s12325-021-01943-z [doi] PST - ppublish SO - Adv Ther. 2022 Jan;39(1):532-543. doi: 10.1007/s12325-021-01943-z. Epub 2021 Nov 19.